Translating gene expression into clinical care: Sarcomas as a paradigm

Journal of Clinical Oncology

Volumn 28, Issue 10, 2010, Pages 1796-1805

  Nielsen, Torsten O ^a   West, Robert B ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BELINOSTAT; BUTYRIC ACID; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 INHIBIITOR; ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RIDAFOROLIMUS; ROMIDEPSIN; SARC 011; SB 939; TRANSCRIPTION FACTOR; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; SOMATOMEDIN C;

ADVANCED CANCER; AMELOBLASTOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CHORDOMA; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL (TOPIC); DERMATOFIBROSARCOMA PROTUBERANS; EPITHELIOID SARCOMA; EWING SARCOMA; FUSION GENE; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TRANSLOCATION; GENETIC HETEROGENEITY; GENETIC STABILITY; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MALIGNANT FIBROUS HISTIOCYTOMA; MALIGNANT TRANSFORMATION; MYXOINFLAMMATORY FIBROBLASTIC SARCOMA; NERVE SHEATH TUMOR; NONHUMAN; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PIGMENTED VILLONODULAR SYNOVITIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SARCOMA CELL; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; SYNOVIAL SARCOMA; ARTICLE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; GENETICS; METABOLISM; PATHOLOGY;

DRUG DELIVERY SYSTEMS; GENE EXPRESSION PROFILING; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGE COLONY-STIMULATING FACTOR; ONCOGENE PROTEINS, FUSION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SARCOMA; SIGNAL TRANSDUCTION;

EID: 77950511643     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.1917     Document Type: Review

References (126)

1. Weiss S, Goldblum J: Enzinger and Weiss's Soft Tissue Tumors (ed 5). Philadelphia, Elsevier Mosby, 2007
2. Ewing J: Diffuse endothelioma of bone. Proceedings of the New York Pathological Society 17-24, 1921
3. Turc-Carel C, Aurias A, Mugneret F, et al: Chromosomes in Ewing's sarcoma: I. An evaluation of 85 cases of remarkable consistency of t(11; 22)(q24;q12). Cancer Genet Cytogenet 32:229-238, 1988
4. Mazur M, Clark H: Gastric stromal tumors: Reappraisal of histogenesis. Am J Surg Pathol 7:507-519, 1983 (Pubitemid 13021488)
5. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998 (Pubitemid 28067289)
6. Wunder JS, Nielsen TO, Maki RG, et al: Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncology 8:513-524, 2007 (Pubitemid 46823060)
7. Borden EC, Baker LH, Bell RS, et al: Soft tissue sarcomas of adults. Clinical Cancer Res 9:1941-1956, 2003
8. Nielsen TO, West RB, Linn SC, et al: Molecular characterisation of soft tissue tumours: A gene expression study. Lancet 359:1301-1307, 2002 (Pubitemid 34310636)
9. Segal NH, Pavlidis P, Antonescu CR, et al: Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 163:691-700, 2003 (Pubitemid 36909430)
10. Henderson S, Guiliano D, Presneau N, et al: A molecular map of mesenchymal tumors. Genome Biology 6:R76, 2005
11. Hallor K, Sciot R, Staaf J, et al: Two genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions. J Pathol 217:716-727, 2009
12. Benjamin RS, Debiec-Rychter M, Le Cesne A, et al: Gastrointestinal stromal tumors II: Medical oncology and tumor response assessment. Semin Oncol 36:302-311, 2009
13. Lemm D, Mügge LO, Mentzel T, et al: Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res and Clinical Oncology 135:653-665, 2009
14. Allander SV, Nupponen NN, Ringner M, et al: Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res 61:8624-8628, 2001 (Pubitemid 34013866)
15. Baird K, Davis S, Antonescu CR, et al: Gene expression profiling of human sarcomas: Insights into sarcoma biology. Cancer Res 65:9226-9235, 2005 (Pubitemid 41507988)
16. Subramanian S, West RB, Corless CL, et al: Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 23:7780-7790, 2004 (Pubitemid 39457028)
17. Lubieniecka JM, de Bruijn DRH, Su L, et al: Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 68:4303-4310, 2008
18. Owen LA, Kowalewski AA, Lessnick SL: EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS ONE 3:e1965, 2008
19. Cheung IY, Feng Y, Danis K, et al: Novel markers of subclinical disease for Ewing family tumors from gene expression profiling. Clinical Cancer Res 13:6978-6983, 2007 (Pubitemid 350276878)
20. Ohali A, Avigad S, Zaizov R, et al: Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene 23:8997-9006, 2004 (Pubitemid 39657791)
21. Schaefer KL, Eisenacher M, Braun Y, et al: Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 44:699-709, 2008
22. Ochi K, Daigo Y, Katagiri T, et al: Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol 24:647-655, 2004
23. Mintz MB, Sowers R, Brown KM, et al: An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65:1748-1754, 2005 (Pubitemid 40478600)
24. Man TK, Chintagumpala M, Visvanathan J, et al: Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 65:8142-8150, 2005 (Pubitemid 41330577)
25. Yang XR, Ng D, Alcorta DA, et al: T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet 41:1176-1178, 2009
26. Jones S, Zhang X, Parsons DW, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806, 2008
27. Ren B, Ping Yu Y, Jing L, et al: Gene expression analysis of human soft tissue leiomyosarcomas. Hum Pathol 34:549-558, 2003 (Pubitemid 36750366)
28. Quade BJ, Wang TY, Somberger K, et al: Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 40:97-108, 2004 (Pubitemid 38579878)
29. Skubitz K, Skubitz A: Differential gene expression in leiomyosarcoma. Cancer 98:1029-1038, 2003 (Pubitemid 37022105)
30. Shmulevich I, Hunt K, El-Naggar A, et al: Tumor specific gene expression profiles in human leiomyosarcoma. Cancer 94:2069-2075, 2002
31. Francis P, Namlos H, Muller C, et al: Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: Hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 8:73, 2007
32. Beck A, Lee C, Witten DM, et al: Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene (e-pub ahead of print on November 9, 2009)
33. Perot G, Derre J, Coindre J-M, et al: Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas. Cancer Res 69:2269-2278, 2009
34. Fletcher CDM: The evolving classification of soft tissue tumours: An update based on the new WHO classification. Histopathology 48:3-12, 2006
35. Subramanian S, Thayanithy V, West RB, et al: Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol 220:58-70, 2010
36. Paoloni M, Davis S, Lana S, et al: Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 10:625, 2009
37. Miller SJ, Jessen WJ, Mehta T, et al: Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Molecular Medicine 1:236-248, 2009
38. Carneiro A, Francis P, Bendahl PO, et al: Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: Different sides of a single coin? Lab Invest 89:668-675, 2009
39. Cleton-Jansen AM, Anninga JK, Briaire-de Bruijn IH, et al: Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer 101:1909-1918, 2009
40. Skubitz KM, Pambuccian S, Manivel JC, et al: Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med 6:23, 2008
41. Lee C-H, Espinosa I, Vrijaldenhoven S, et al: Prognostic significance of macrophage infiltration in leiomyosarcomas. Clinical Cancer Res 14:1423-1430, 2008 (Pubitemid 351413925)
42. Neale G, Su X, Morton CL, et al: Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 14:4572-4583, 2008
43. Whiteford CC, Bilke S, Greer BT, et al: Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 67:32-40, 2007 (Pubitemid 46142757)
44. Agaram NP, Besmer P, Wong GC, et al: Pathologic and molecular heterogeneity in imatinibstable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 13:170-181, 2007 (Pubitemid 46121866)
45. Singer S, Socci ND, Ambrosini G, et al: Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 67:6626-6636, 2007 (Pubitemid 47105508)
46. Nakayama R, Nemoto T, Takahashi H, et al: Gene expression analysis of soft tissue sarcomas: Characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 20:749-759, 2007 (Pubitemid 46933446)
47. Davicioni E, Finckenstein FG, Shahbazian V, et al: Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 66:6936-6946, 2006 (Pubitemid 44197668)
48. Detwiller KY, Fernando NT, Segal NH, et al: Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res 65:5881-5889, 2005 (Pubitemid 40911194)
49. Morgan T, Atkins GJ, Trivett MK, et al: Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 167:117-128, 2005 (Pubitemid 40884775)
50. Segal NH, Pavlidis P, Noble WS, et al: Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol 21:1775-1781, 2003 (Pubitemid 46638591)
51. Linn SC, West RB, Pollack JR, et al: Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol 163:2383-2395, 2003 (Pubitemid 37466479)
52. Nagayama S, Katagiri T, Tsunoda T, et al: Genome-wide Analysis of Gene Expression in Synovial Sarcomas Using a cDNA Microarray. Cancer Res 62:5859-5866, 2002 (Pubitemid 35204746)
53. Haldar M, Hancock JD, Coffin CM, et al: A conditional mouse model of synovial sarcoma: Insights into a myogenic origin. Cancer Cell 11:375-388, 2007 (Pubitemid 46518310)
54. Tomlins SA, Rhodes DR, Perner S, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648, 2005 (Pubitemid 41528150)
55. Ioannidis JPA, Allison DB, Ball CA, et al: Repeatability of published microarray gene expression analyses. Nat Genet 41:149-155, 2009
56. Terry J, Saito T, Subramanian S, et al: TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 31:240-246, 2007 (Pubitemid 46175025)
57. Brazma A, Hingamp P, Quackenbush J, et al: Minimum information about a microarray experiment (MIAME) - toward standards for microarray data. Nat Genet 29:365-371, 2001 (Pubitemid 34326681)
58. Brazma A: Minimum information about a microarray experiment (MIAME) - successes, failures, challenges. The Scientific World 9:420-423, 2009
59. Barrett T, Troup DB, Wilhite SE, et al: NCBI GEO: Mining tens of millions of expression profiles-database and tools update. Nucleic Acids Res 35:D760-765, 2007
60. Cronin M, Pho M, Dutta D, et al: Measurement of gene expression in archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164:35-42, 2004 (Pubitemid 38364587)
61. Ravo M, Mutarelli M, Ferraro L, et al: Quantitative expression profiling of highly degraded RNA from formalin-fixed, paraffin-embedded breast tumor biopsies by oligonucleotide microarrays. Lab Invest 88:430-440, 2008 (Pubitemid 351432771)
62. Roberts RA, Sabalos CM, LeBlanc ML, et al: Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Lab Invest 87:979-997, 2007 (Pubitemid 47429191)
63. Geiss GK, Bumgarner RE, Birditt B, et al: Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotech 26:317-325, 2008 (Pubitemid 351355126)
64. Blay P, Astudillo A, Buesa JM, et al: Protein kinase C θ is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clinical Cancer Res 10:4089-4095, 2004 (Pubitemid 38812487)
65. Motegi A, Sakurai S, Nakayama H, et al: PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors. Pathol Int 55:106-112, 2005 (Pubitemid 40477221)
66. Voduc D, Kenney C, Nielsen TO: Tissue microarrays in clinical oncology. Semin Radiat Oncol 18:89-97, 2008 (Pubitemid 351296453)
67. West RB, Harvell J, Linn SC, et al: Apo D in soft tissue tumors: A novel marker for dermatofibrosarcoma protuberans. Am J Surg Pathol 28:1063-1069, 2004 (Pubitemid 38971432)
68. Espinosa I, Lee CH, Kim MK, et al: A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 32:210-218, 2008 (Pubitemid 351172135)
69. Miettinen M, Wang ZF, Lasota J: DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: A study of 1840 cases. Am J Surg Pathol 33:1401-1408, 2009
70. Shing DC, McMullan DJ, Roberts P, et al: FUS/ERG gene fusions in Ewing's tumors. Cancer Res 63:4568-4576, 2003 (Pubitemid 36951031)
71. Delattre O, Zucman J, Plougastel B, et al: Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359:162-165, 1992
72. Zucman J, Melot T, Desmaze C, et al: Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 12:4481-4487, 1993 (Pubitemid 23330254)
73. Jeon IS, Davis JN, Braun BS, et al: A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 10:1229-1234, 1995
74. Kaneko Y, Yoshida K, Handa M, et al: Fusion of an ETS-family gene, EIAF, to EWS by t(17; 22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes, Chromosomes Cancer 15:115-121, 1996
75. Peter M, Couturier J, Pacquement H, et al: A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 14:1159-1164, 1997 (Pubitemid 27141917)
76. Zucman J, Delattre O, Desmaze C, et al: EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 4:341-345, 1993 (Pubitemid 23231480)
77. Antonescu CR, Nafa K, Segal NH, et al: EWS-CREB1: A recurrent variant fusion in clear cell sarcoma - association with gastrointestinal location and absence of melanocytic differentiation. Clinical Cancer Res 12:5356-5362, 2006 (Pubitemid 44497248)
78. Clark J, Benjamin H, Gill S, et al: Fusion of the EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma. Oncogene 12:229-235, 1996 (Pubitemid 26042560)
79. Sjogren H, Meis-Kindblom J, Kindblom L-G, et al: Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma. Cancer Res 59:5064-5067, 1999 (Pubitemid 29503959)
80. Ladanyi M, Gerald W: Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res 54:2837-2840, 1994 (Pubitemid 24187757)
81. Crozat A, Aman P, Mandahl N, et al: Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 363:640-644, 1993 (Pubitemid 23227627)
82. Panagopoulos I, Höglund M, Mertens F, et al: Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene 12:489-494, 1996 (Pubitemid 26059642)
83. Mertens F, Fletcher CDM, Antonescu CR, et al: Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS//CREB3L1 fusion gene. Lab Invest 85:408-415, 2005 (Pubitemid 40333157)
84. Galili N, Davis RJ, Fredericks WJ, et al: Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 5:230-235, 1993 (Pubitemid 23330384)
85. Davis RJ, D'Cruz CM, Lovell MA, et al: Fusion of PAX7 to FKHR by the variant t(1;13)(p36; q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 54:2869-2872, 1994 (Pubitemid 24187765)
86. Wachtel M, Dettling M, Koscielniak E, et al: Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 64:5539-5545, 2004 (Pubitemid 39095545)
87. Ladanyi M, Lui MY, Antonescu CR, et al: The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 20:48-57, 2001 (Pubitemid 32142337)
88. Koontz JI, Soreng AL, Nucci M, et al: Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci U S A 98:6348-6353, 2001 (Pubitemid 32488241)
89. Micci F, Panagopoulos I, Bjerkehagen B, et al: Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res 66:107-112, 2006 (Pubitemid 43166015)
90. Crew AJ, Clark J, Fisher C, et al: Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J 14:2333-2340, 1995
91. Storlazzi CT, Mertens F, Mandahl N, et al: A novel fusion gene, SS18L1/SSX1, in synovial sarcoma. Genes, Chromosomes and Cancer 37:195-200, 2003 (Pubitemid 36529787)
92. Skytting B, Nilsson G, Brodin B, et al: A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst 91:974-975, 1999 (Pubitemid 29275883)
93. de Bruijn DRH, Nap JP, van Kessel A: The (Epi)genetics of human synovial sarcoma. Genes Chromosomes Cancer 46:107-117, 2007
94. Lim F, Soulez M, Koczan D, et al: A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas. Oncogene 17:2013-2018, 1998 (Pubitemid 28488471)
95. Soulez M, Saurin AJ, Freemont PS, et al: SSX and the synovial-sarcoma- specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex. Oncogene 18:2739-2746, 1999 (Pubitemid 29237662)
96. van der Vlag J, Otte AP: Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 23:474-478, 1999
97. Furuyama T, Banerjee R, Breen TR, et al: SIR2 is required for polycomb silencing and is associated with an E(Z) histone methyltransferase complex. Curr Biol 14:1812-1821, 2004
98. Yochum GS, Ayer DE: Pf1, a Novel PHD zinc finger protein that links the TLE corepressor to the mSin3A-histone deacetylase complex. Mol Cell Biol 21:4110-4118, 2001 (Pubitemid 32565293)
99. Ito T, Ouchida M, Ito S, et al: SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex. Lab Invest 84:1484-1490, 2004 (Pubitemid 39482165)
100. de Bruijn DRH, Allander SV, van Dijk AHA, et al: The synovial sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer Res 66:9474-9482, 2006 (Pubitemid 44623645)
101. Ito T, Ouchida M, Morimoto Y, et al: Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett 224:311-319, 2005 (Pubitemid 40725851)
102. Hrzenjak A, Moinfar F, Kremser M-L, et al: Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Molecular Cancer Therapeutics 5:2203-2210, 2006 (Pubitemid 44530456)
103. Hrzenjak A, Kremser ML, Strohmeier B, et al: SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol 216:495-504, 2008
104. Richter GH, Plehm S, Fasan A, et al: EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuroectodermal differentiation. PNAS 106:5324-5329, 2009
105. Sonnemann J, Dreyer L, Hartwig M, et al: Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. Journal of Cancer Res and Clinical Oncology 133:847-858, 2007 (Pubitemid 350218911)
106. Sakimura R, Tanaka K, Nakatani F, et al: Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer 116:784-792, 2005 (Pubitemid 41099711)
107. Liu S, Cheng H, Kwan W, et al: Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models. Molecular Cancer Therapeutics 7:1751-1761, 2008
108. Shankar S, Srivastava RK: Histone deacetylase inhibitors: Mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 615:261-298, 2008
109. Liu P, Cheng H, Roberts TM, et al: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644, 2009
110. Hernando E, Charytonowicz E, Dudas ME, et al: The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 13:748-753, 2007 (Pubitemid 46889749)
111. Zhu Q-S, Ren W, Korchin B, et al: Soft tissue sarcoma cells are highly sensitive to AKT blockade: A role for p53-independent up-regulation of GADD45{alpha}. Cancer Res 68:2895-2903, 2008
112. Chawla SP, Tolcher AW, Staddon AP, et al: Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. J Clin Oncol 24:521s, 2006 (suppl; abstr 9505)
113. Mita M, Sankhala K, Abdel-Karim I, et al: Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opinion on Investigational Drugs 17:1947-1954, 2008
114. Rikhof B, de Jong S, Suurmeijer AJ, et al: The insulin-like growth factor system and sarcomas. J Pathol 217:469-482, 2009
115. Subbiah V, Anderson P, Lazar A, et al: Ewing's sarcoma: Standard and experimental treatment options. Current Treatment Options in Oncology 10:126-140, 2009
116. Huang H-Y, West RB, Tzeng C-C, et al: Immunohistochemical and biogenetic features of diffuse-type tenosynovial giant cell tumors: The potential roles of cyclin A, P53, and deletion of 15q in sarcomatous transformation. Clinical Cancer Res 14:6023-6032, 2008
117. West RB, Rubin BP, Miller MA, et al: A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A 103:690-695, 2006 (Pubitemid 43153087)
118. Cupp JS, Miller MA, Montgomery KD, et al: Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol 31:970-976, 2007 (Pubitemid 47165154)
119. Möller E, Mandahl N, Mertens F, et al: Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors. Genes Chromosomes Cancer 47:21-25, 2008 (Pubitemid 350191460)
120. Blay JY, El Sayadi H, Thiesse P, et al: Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 19:821-822, 2008 (Pubitemid 351461057)
121. Horoschak M, Tran PT, Bachireddy P, et al: External beam radiation therapy enhances local control in pigmented villonodular synovitis. International Journal of Radiation Oncology, Biology, Physics 75:183-187, 2009
122. Espinosa I, Beck AH, Lee C-H, et al: Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. Am J Pathol 174:2347-2356, 2009
123. Miselis NR, Wu ZJ, Van Rooijen N, et al: Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Molecular Cancer Therapeutics 7:788-799, 2008 (Pubitemid 351551032)
124. Gupta A, Church D, Barnes D, et al: Cut to the chase: On the need for genotype-specific soft tissue sarcoma trials. Ann Oncol 20:399-400, 2009
125. Shah SP, Kobel M, Senz J, et al: Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 360:2719-2729, 2009
126. Heinrich MC, Owzar K, Corless CL, et al: Correlation of kinase genotype and clinical outcome in the north american intergroup phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26:5360-5367, 2008